Overview
Lobbying Costs
75,000€
Financial year: Jan 2018 - Dec 2018
Lobbyists (Full time equivalent)
0.25 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
2
Lobbying Costs over the years
-
Info
ALNYLAM PHARMACEUTICALS (ALNY)
EU Transparency Register
838328429683-62 First registered on 18 Jan 2018
Goals / Remit
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to
transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi
therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high
unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by
its robust discovery platform and deep pipeline of investigational medicines.Main EU files targeted
Alnylam is committed to making the therapies we develop available to those who will benefit from them. We seek to be involved in policy developments that improve regulatory processes for pharmaceuticals and ensure the right environment for research,
innovation and industry in Europe. We aim at participating in debates around improved and equal access to innovative medicines for
patients through open dialogues with European policy-makers.Address
Head Office
Dammstrasse 19
Zug 6300
SWITZERLAND -
People
Total lobbyists declared
1
Employment time Lobbyists 25% 1 Lobbyists (Full time equivalent)
0.25
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
To date, Alnylam has only one employee dedicated to EU Affairs and relations with EU institutions. This specific employee has
other responsabilities accross Europr that do not relate to (i) Government Affairs (ii) nor the EU institutions and therefore do not fall
in the scope of the Transparency Register. Other Alnylam employees may occasionally be involved on EU matters, but their
involvment is limited to occasional participation in Trade Association meeting or external event. This does not exceed 10% of their
time and therefore do not fall under the scope of the Transparency Register.Person in charge of EU relations
Mr Julien Patris (Associate Director Market access & Policy Europe & Canada)
Person with legal responsibility
Ms Theresa Heggie (SVP Head of Europe and Canada)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Alnylam is Member of European Confederation of Pharmaceutical Entrepreneurs (EUCOPE, http://www.eucope.org/en)
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2018 - Dec 2018
Lobbying costs for closed financial year
75,000€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
None
Other activities
None declared
Meetings
Meetings
2 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 26 Sep 2018 Location Brussels Subject Health Research in Europe Cabinet Cabinet of Commissioner Carlos Moedas Portfolio Research, Science and Innovation Attending - Keith Sequeira (Cabinet member)
-
Date 25 Sep 2018 Location Brussels Subject EU action in life science and innovation + investment and growth in Europe Cabinet Cabinet of Vice-President Jyrki Katainen Portfolio Jobs, Growth, Investment and Competitiveness Attending - Marika Lautso-Mousnier (Cabinet member)